Clinical Trial Update: A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated the relative bioavailability of a fixed-dose combination tablet of ambrisentan and tadalafil in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Pulmonary Hypertension

Drugs mentioned

• Adcirca (tadalafil)
• LETAIRIS (ambrisentan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypertension, Pulmonary | Phase 1 | Status: COMPLETED | Results posted: 2019-01-22